精氨酸
谷氨酰胺
瓜氨酸
常染色体显性多囊肾病
生物
精氨酸脱氨酶
癌症研究
多囊肾病
包装D1
细胞生物学
蛋白质精氨酸甲基转移酶5
内科学
内分泌学
肾
生物化学
氨基酸
医学
甲基转移酶
甲基化
基因
作者
Josephine F. Trott,Vicki J. Hwang,Tatsuto Ishimaru,Kenneth J. Chmiel,Julie Xia Zhou,Kyuhwan Shim,Benjamin J. Stewart,Moe R. Mahjoub,Kuang‐Yu Jen,Dinesh Kumar Barupal,Xiaogang Li,Robert H. Weiss
出处
期刊:American Journal of Physiology-renal Physiology
[American Physical Society]
日期:2018-10-03
卷期号:315 (6): F1855-F1868
被引量:52
标识
DOI:10.1152/ajprenal.00025.2018
摘要
Research into metabolic reprogramming in cancer has become commonplace, yet this area of research has only recently come of age in nephrology. In light of the parallels between cancer and autosomal dominant polycystic kidney disease (ADPKD), the latter is currently being studied as a metabolic disease. In clear cell renal cell carcinoma (RCC), which is now considered a metabolic disease, we and others have shown derangements in the enzyme arginosuccinate synthase 1 (ASS1), resulting in RCC cells becoming auxotrophic for arginine and leading to a new therapeutic paradigm involving reducing extracellular arginine. Based on our earlier finding that glutamine pathways are reprogrammed in ARPKD, and given the connection between arginine and glutamine synthetic pathways via citrulline, we investigated the possibility of arginine reprogramming in ADPKD. We now show that, in a remarkable parallel to RCC, ASS1 expression is reduced in murine and human ADPKD, and arginine depletion results in a dose-dependent compensatory increase in ASS1 levels as well as decreased cystogenesis in vitro and ex vivo with minimal toxicity to normal cells. Nontargeted metabolomics analysis of mouse kidney cell lines grown in arginine-deficient versus arginine-replete media suggests arginine-dependent alterations in the glutamine and proline pathways. Thus, depletion of this conditionally essential amino acid by dietary or pharmacological means, such as with arginine-degrading enzymes, may be a novel treatment for this disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI